JP2018009002A5 - - Google Patents

Download PDF

Info

Publication number
JP2018009002A5
JP2018009002A5 JP2017155229A JP2017155229A JP2018009002A5 JP 2018009002 A5 JP2018009002 A5 JP 2018009002A5 JP 2017155229 A JP2017155229 A JP 2017155229A JP 2017155229 A JP2017155229 A JP 2017155229A JP 2018009002 A5 JP2018009002 A5 JP 2018009002A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
cells
mesenchymal stem
cultured
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017155229A
Other languages
English (en)
Japanese (ja)
Other versions
JP6757300B2 (ja
JP2018009002A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018009002A publication Critical patent/JP2018009002A/ja
Publication of JP2018009002A5 publication Critical patent/JP2018009002A5/ja
Application granted granted Critical
Publication of JP6757300B2 publication Critical patent/JP6757300B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2017155229A 2004-03-22 2017-08-10 間葉幹細胞及びその使用法 Expired - Lifetime JP6757300B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55511804P 2004-03-22 2004-03-22
US60/555,118 2004-03-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017003854A Division JP6382360B2 (ja) 2004-03-22 2017-01-13 間葉幹細胞及びその使用法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018190636A Division JP6757383B2 (ja) 2004-03-22 2018-10-09 間葉幹細胞及びその使用法
JP2020047240A Division JP7033159B2 (ja) 2004-03-22 2020-03-18 間葉幹細胞及びその使用法

Publications (3)

Publication Number Publication Date
JP2018009002A JP2018009002A (ja) 2018-01-18
JP2018009002A5 true JP2018009002A5 (enExample) 2018-04-19
JP6757300B2 JP6757300B2 (ja) 2020-09-16

Family

ID=46060822

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2012058539A Expired - Lifetime JP6114500B2 (ja) 2004-03-22 2012-03-15 間葉幹細胞及びその使用法
JP2014241859A Expired - Lifetime JP5997237B2 (ja) 2004-03-22 2014-11-28 間葉幹細胞及びその使用法
JP2017003854A Expired - Lifetime JP6382360B2 (ja) 2004-03-22 2017-01-13 間葉幹細胞及びその使用法
JP2017155229A Expired - Lifetime JP6757300B2 (ja) 2004-03-22 2017-08-10 間葉幹細胞及びその使用法
JP2018190636A Expired - Lifetime JP6757383B2 (ja) 2004-03-22 2018-10-09 間葉幹細胞及びその使用法
JP2020047240A Expired - Lifetime JP7033159B2 (ja) 2004-03-22 2020-03-18 間葉幹細胞及びその使用法
JP2021140167A Expired - Lifetime JP7546239B2 (ja) 2004-03-22 2021-08-30 間葉幹細胞及びその使用法
JP2023023996A Pending JP2023065486A (ja) 2004-03-22 2023-02-20 間葉幹細胞及びその使用法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2012058539A Expired - Lifetime JP6114500B2 (ja) 2004-03-22 2012-03-15 間葉幹細胞及びその使用法
JP2014241859A Expired - Lifetime JP5997237B2 (ja) 2004-03-22 2014-11-28 間葉幹細胞及びその使用法
JP2017003854A Expired - Lifetime JP6382360B2 (ja) 2004-03-22 2017-01-13 間葉幹細胞及びその使用法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018190636A Expired - Lifetime JP6757383B2 (ja) 2004-03-22 2018-10-09 間葉幹細胞及びその使用法
JP2020047240A Expired - Lifetime JP7033159B2 (ja) 2004-03-22 2020-03-18 間葉幹細胞及びその使用法
JP2021140167A Expired - Lifetime JP7546239B2 (ja) 2004-03-22 2021-08-30 間葉幹細胞及びその使用法
JP2023023996A Pending JP2023065486A (ja) 2004-03-22 2023-02-20 間葉幹細胞及びその使用法

Country Status (5)

Country Link
JP (8) JP6114500B2 (enExample)
AT (1) ATE556134T1 (enExample)
CA (3) CA3135582A1 (enExample)
ES (7) ES2544689T3 (enExample)
TR (1) TR201901268T4 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544689T3 (es) * 2004-03-22 2015-09-02 Mesoblast International Sàrl Células madre mesenquimales y usos de las mismas
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2014098960A2 (en) * 2012-05-16 2014-06-26 The Johns Hopkins University Stem cells as an individualized maternal therapy for prevention of prematurity
JP2016210730A (ja) * 2015-05-08 2016-12-15 上田　実 医薬組成物及びその製造方法並びに医薬品
US11401502B2 (en) 2016-11-15 2022-08-02 Kaneka Corporation Cell population comprising mesenchymal stem cells derived from fetal appendage, method for producing the same, and pharmaceutical composition
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
WO2019132026A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
EP3984596A4 (en) 2019-06-14 2023-06-21 Kaneka Corporation POPULATION OF CELLS COMPRISING MESENCHYMATOUS CELLS, PHARMACEUTICAL COMPOSITION COMPRISING THEM AND METHOD FOR PRODUCTION THEREOF
CA3148582A1 (en) * 2019-08-15 2021-02-18 Nextcell Pharma Ab Allogeneic composition for treatment of cns disorders
CN113813288B (zh) * 2021-08-11 2024-02-13 谢岩 间充质干细胞及包含其的组合物用于制备治疗烧伤难愈创面的药物的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0651641B2 (ja) * 1983-08-29 1994-07-06 株式会社ミドリ十字 ガンマ・インターフェロン組成物
WO1987005518A1 (en) * 1986-03-17 1987-09-24 Schering Corporation Treatment of cancers with gamma interferon
AU2701895A (en) * 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
JP2000508922A (ja) * 1996-04-26 2000-07-18 ケース ウエスターン リザーブ ユニバーシティ 間葉幹細胞を用いる皮膚再生
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DE69929681T2 (de) * 1998-03-18 2006-10-26 Osiris Therapeutics, Inc. Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
JP2002510655A (ja) * 1998-04-03 2002-04-09 オシリス セラピューティクス，インコーポレイテッド 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用
AU2925401A (en) * 2000-01-19 2001-07-31 Parkash S Gill Methods and compositions for antisense vegf oligonucleotides
DE60143517D1 (de) * 2000-04-25 2011-01-05 Osiris Therapeutics Inc Wiederherstellung der gelenken mit mesenchymalen stammzellen
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
JP3897343B2 (ja) * 2002-08-01 2007-03-22 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
EP1583422B1 (en) * 2002-12-05 2016-03-30 Case Western Reserve University Cell-based therapies for ischemia
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
ES2544689T3 (es) * 2004-03-22 2015-09-02 Mesoblast International Sàrl Células madre mesenquimales y usos de las mismas

Similar Documents

Publication Publication Date Title
JP2018009002A5 (enExample)
JP2017080507A5 (enExample)
Xie et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?
JP2018109052A5 (enExample)
JP2017081972A5 (enExample)
Amoah et al. Immunopathogenesis of myocarditis: the interplay between cardiac fibroblast cells, dendritic cells, macrophages and CD 4+ T cells
HRP20110763T1 (hr) Makrolidni konjugati s protuupalnom aktivnošću
CN104884076B (zh) 利用了hmgb1片段的心肌梗塞的治疗方法
JP2018526447A5 (enExample)
JP2011116788A5 (enExample)
Mohammadian et al. Effect of bone marrow derived mesenchymal stem cells on lung pathology and inflammation in ovalbumin-induced asthma in mouse
JP2017525364A5 (enExample)
Che et al. Mesenchymal stem/stromal cells in the pathogenesis and regenerative therapy of inflammatory bowel diseases
WO2018228538A1 (zh) 重组单纯疱疹病毒及其制备方法和应用
JP2016505023A5 (enExample)
JP2011520434A5 (enExample)
JP2012506394A5 (enExample)
JP2013519363A5 (enExample)
Swedin et al. Patient stratification and the unmet need in asthma
Bamba et al. Can mesenchymal stem cell therapy be the interim management of COVID-19?
Cata et al. How regional analgesia might reduce postoperative cancer recurrence
Halder et al. Glycyrrhizin loaded hyaluronic acid nanofiber-based artificial saliva for the management of oral mucositis: Preparation, optimization and in-vitro evaluation
JP2016502980A5 (enExample)
JP2017509633A5 (enExample)
Portacci et al. Dupilumab and Blood Eosinophilia: A Disease‐Specific Phenomenon?